Details.
FDA-approved esketamine nasal spray administered in the clinic under physician supervision for people with treatment-resistant depression or major depressive disorder. Treatment includes medical monitoring, physician and nursing oversight, and preparation and aftercare guidance. Patients should avoid alcohol, marijuana, and other substances before sessions, arrange transportation home, and remain at the clinic for observation. The induction phase includes 8 treatments over 4 weeks, with each treatment lasting two hours. Follow-up may include monthly optimization and individualized maintenance treatment.